Eli Lilly and - LLY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $384.11
  • Forecasted Upside: 12.81%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.6 (-0.47%)

This chart shows the closing price for LLY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eli Lilly and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

Analyst Price Target is $384.11
▲ +12.81% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Eli Lilly and in the last 3 months. The average price target is $384.11, with a high forecast of $440.00 and a low forecast of $286.00. The average price target represents a 12.81% upside from the last price of $340.50.

This chart shows the closing price for LLY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 contributing investment analysts is to buy stock in Eli Lilly and. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2023BarclaysBoost TargetOverweight$395.00 ➝ $400.00Low
12/16/2022SVB LeerinkBoost TargetOutperform$384.00 ➝ $410.00Low
12/15/2022UBS GroupLower TargetBuy$428.00 ➝ $420.00Low
12/14/2022Morgan StanleyLower TargetOverweight$446.00 ➝ $440.00Low
12/14/2022JPMorgan Chase & Co.Boost Target$380.00 ➝ $400.00Low
12/9/2022UBS GroupBoost Target$407.00 ➝ $428.00Low
12/8/2022Wells Fargo & CompanyBoost TargetEqual Weight$365.00 ➝ $375.00Low
12/7/2022GuggenheimBoost TargetBuy$399.00 ➝ $401.00Low
12/6/2022Credit Suisse GroupBoost TargetOutperform$395.00 ➝ $400.00Low
12/6/2022Morgan StanleyBoost TargetOverweight$436.00 ➝ $446.00Low
12/5/2022CowenBoost TargetOutperform$390.00 ➝ $430.00Low
12/5/2022CowenBoost Target$390.00 ➝ $430.00Low
11/22/2022Berenberg BankBoost TargetBuy$345.00 ➝ $375.00Low
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$395.00Low
11/17/2022Morgan StanleyLower TargetOverweight$441.00 ➝ $436.00Low
11/15/2022Truist FinancialBoost Target$400.00 ➝ $421.00Low
11/8/2022The Goldman Sachs GroupBoost TargetNeutral$281.00 ➝ $313.00Low
11/2/2022SVB LeerinkBoost TargetOutperform$341.00 ➝ $384.00Low
11/2/2022Morgan StanleyBoost TargetOverweight$408.00 ➝ $441.00Low
11/2/2022Wells Fargo & CompanyBoost TargetEqual Weight$305.00 ➝ $365.00Low
11/2/2022BarclaysBoost TargetOverweight$355.00 ➝ $395.00Low
10/12/2022Morgan StanleyLower TargetOverweight$412.00 ➝ $408.00Low
9/30/2022ArgusBoost Target$315.00 ➝ $360.00Low
9/22/2022UBS GroupUpgradeNeutral ➝ Buy$335.00 ➝ $363.00Low
9/7/2022Morgan StanleyBoost TargetOverweight$395.00 ➝ $412.00Low
9/6/2022BMO Capital MarketsBoost TargetOutperform$369.00 ➝ $396.00Low
8/25/2022CitigroupBoost Target$285.00 ➝ $370.00Low
7/27/2022UBS GroupBoost TargetOutperform$335.00Low
7/8/2022Morgan StanleyBoost TargetOverweight$369.00 ➝ $395.00N/A
7/7/2022BarclaysBoost TargetOverweight$333.00 ➝ $355.00N/A
6/1/2022JPMorgan Chase & Co.Boost Target$340.00 ➝ $355.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperform$341.00Low
5/2/2022MizuhoBoost Target$315.00 ➝ $356.00Low
4/29/2022Morgan StanleyBoost Target$364.00 ➝ $369.00High
4/29/2022Wells Fargo & CompanyBoost Target$280.00 ➝ $305.00Medium
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$234.00 ➝ $264.00Low
4/6/2022Morgan StanleyBoost TargetOverweight$265.00 ➝ $364.00High
3/17/2022Bank of AmericaBoost Target$300.00 ➝ $315.00Medium
3/10/2022Daiwa Capital MarketsInitiated CoverageOutperform$286.00Medium
2/4/2022MizuhoLower TargetBuy$302.00 ➝ $293.00High
2/4/2022Morgan StanleyLower TargetOverweight$272.00 ➝ $265.00Medium
1/24/2022Morgan StanleyLower TargetOverweight$275.00 ➝ $272.00Low
1/21/2022DZ BankUpgradeHold ➝ Buy$291.00Medium
1/5/2022MizuhoBoost Target$272.00 ➝ $302.00High
1/4/2022Wells Fargo & CompanyBoost TargetEqual Weight$270.00 ➝ $280.00Low
1/3/2022Sanford C. BernsteinBoost TargetMarket Perform$250.00 ➝ $300.00High
12/20/2021Berenberg BankBoost TargetBuy$270.00 ➝ $305.00High
12/20/2021BarclaysBoost TargetOverweight$280.00 ➝ $325.00High
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$236.00High
12/16/2021MizuhoInitiated CoverageBuy$272.00Low
12/16/2021BMO Capital MarketsBoost TargetOutperform$311.00 ➝ $320.00Low
12/16/2021Bank of AmericaBoost TargetBuy$285.00 ➝ $300.00Low
12/16/2021JPMorgan Chase & Co.Reiterated RatingBuyLow
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$270.00Low
11/24/2021Truist FinancialBoost TargetBuy$262.00 ➝ $301.00Low
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$311.00Medium
10/27/2021MizuhoLower TargetBuy$279.00 ➝ $272.00Low
10/11/2021Berenberg BankUpgradeHold ➝ Buy$240.00 ➝ $270.00Low
9/29/2021CitigroupUpgradeNeutral ➝ Buy$210.00 ➝ $265.00High
9/24/2021JPMorgan Chase & Co.Reiterated RatingBuy$300.00Low
8/30/2021CowenBoost TargetOutperform$250.00 ➝ $300.00Low
8/9/2021ArgusBoost TargetBuy$225.00 ➝ $300.00Medium
8/5/2021DZ BankUpgradeHold ➝ Buy$288.00Low
8/4/2021JPMorgan Chase & Co.Boost TargetTop Pick ➝ Overweight$270.00 ➝ $300.00Medium
8/4/2021Morgan StanleyBoost TargetOverweight$207.00 ➝ $275.00High
8/4/2021MizuhoBoost TargetBuy$250.00 ➝ $279.00High
7/27/2021Truist FinancialInitiated CoverageBuy$262.00Low
7/7/2021MizuhoReiterated RatingBuy$250.00Low
7/6/2021BarclaysBoost TargetOverweight$227.00 ➝ $250.00Low
7/2/2021Truist FinancialBoost TargetBuy ➝ Buy$225.00 ➝ $262.00Low
6/24/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$245.00 ➝ $300.00High
6/24/2021CowenBoost TargetPositive ➝ Outperform$235.00 ➝ $250.00High
6/15/2021JPMorgan Chase & Co.Boost TargetOverweight$240.00 ➝ $260.00Low
6/14/2021The Goldman Sachs GroupBoost TargetPositive ➝ Conviction-Buy$252.00 ➝ $270.00Low
6/8/2021Truist FinancialReiterated RatingBuy$225.00Medium
4/28/2021Morgan StanleyLower TargetOverweight$217.00 ➝ $207.00Medium
4/28/2021MizuhoLower TargetBuy$228.00 ➝ $216.00Medium
4/28/2021BarclaysLower TargetOverweight$232.00 ➝ $227.00Medium
3/15/2021Truist FinancialBoost TargetBuy$215.00 ➝ $225.00High
2/12/2021CowenBoost TargetOutperform$195.00 ➝ $235.00Low
2/4/2021Morgan StanleyBoost TargetOverweight$190.00 ➝ $217.00Medium
2/1/2021Truist FinancialBoost Target$200.00 ➝ $215.00Low
2/1/2021MizuhoBoost TargetBuy$222.00 ➝ $228.00Low
2/1/2021BarclaysBoost TargetOverweight$190.00 ➝ $232.00Low
1/22/2021Bank of AmericaBoost TargetBuy$195.00 ➝ $225.00Medium
1/19/2021MizuhoUpgradeNeutral ➝ Buy$164.00 ➝ $222.00N/A
1/12/2021Truist FinancialBoost Target$182.00 ➝ $200.00Medium
12/16/2020MizuhoBoost TargetNeutral$156.00 ➝ $164.00High
12/10/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$147.00 ➝ $183.00Medium
11/17/2020MizuhoLower TargetNeutral$164.00 ➝ $156.00Low
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$150.00Low
10/28/2020Morgan StanleyLower TargetOverweight$176.00 ➝ $170.00Low
10/23/2020Truist FinancialInitiated CoverageBuy$180.00Medium
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$190.00 ➝ $200.00Low
9/29/2020Berenberg BankInitiated CoverageHold$144.00Medium
9/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$149.55 ➝ $176.00High
8/14/2020Morgan StanleyBoost TargetEqual Weight$148.00 ➝ $157.00Low
6/29/2020MizuhoBoost TargetNeutral$155.00 ➝ $164.00Low
6/19/2020Bank of AmericaReiterated RatingBuy$180.00Low
6/17/2020JPMorgan Chase & Co.Boost TargetOverweight$175.00 ➝ $190.00Low
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$182.00High
4/24/2020MizuhoBoost TargetBuy$148.00 ➝ $155.00Low
4/24/2020CfraBoost TargetHold$146.00 ➝ $167.00Low
4/24/2020Cantor FitzgeraldBoost TargetOverweight$156.00 ➝ $185.00Low
4/20/2020UBS GroupDowngradeBuy ➝ Neutral$157.00 ➝ $158.00High
4/19/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
4/15/2020CowenBoost TargetOutperform$145.00 ➝ $160.00Medium
4/9/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$148.00Low
4/2/2020MizuhoReiterated RatingHold$148.00Medium
4/2/2020Morgan StanleyLower TargetOverweight ➝ Equal Weight$150.00 ➝ $148.00High
3/11/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$168.00Medium
2/27/2020BarclaysInitiated CoverageOverweightHigh
2/18/2020Cantor FitzgeraldReiterated RatingBuy$156.00Low
2/5/2020MizuhoInitiated CoverageNeutral$148.00Low
2/3/2020Cantor FitzgeraldReiterated RatingBuy$156.00Medium
12/30/2019ArgusBoost TargetBuy$145.00 ➝ $165.00Low
12/18/2019JPMorgan Chase & Co.Boost TargetOverweight$140.00 ➝ $150.00High
12/18/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$116.00 ➝ $150.00High
12/2/2019Cantor FitzgeraldReiterated RatingBuy$143.00Low
10/17/2019UBS GroupLower TargetBuy$134.00 ➝ $133.00Low
10/16/2019Bank of AmericaInitiated CoverageBuy$133.00Low
9/10/2019Bank of AmericaSet TargetNeutral$118.00 ➝ $120.00High
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$135.00Low
5/1/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$130.00 ➝ $133.00Low
4/30/2019Cantor FitzgeraldReiterated RatingBuy$143.00Medium
4/23/2019Edward JonesUpgradeHold ➝ Buy$117.49Low
4/22/2019BMO Capital MarketsLower TargetOutperform$130.00Medium
4/14/2019BarclaysReiterated RatingBuy$140.00Low
4/11/2019GuggenheimDowngradeBuy ➝ Neutral$125.84Low
3/22/2019Credit Suisse GroupSet TargetHold$121.00Low
3/21/2019Bank of AmericaSet TargetHold$129.00Low
3/20/2019UBS GroupInitiated CoverageBuy$140.00 ➝ $74.51Low
3/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$140.00Low
2/26/2019CitigroupSet TargetHold$124.00Medium
2/8/2019UBS GroupLower TargetAverage$107.53 ➝ $100.00Low
2/4/2019Cantor FitzgeraldReiterated RatingBuyLow
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$131.00Low
1/20/2019BarclaysReiterated RatingBuy$130.00Low
12/27/2018ArgusReiterated RatingBuyMedium
12/24/2018BMO Capital MarketsBoost TargetOutperform$124.00 ➝ $132.00Low
12/20/2018Morgan StanleySet TargetHold$116.00High
12/19/2018BMO Capital MarketsReiterated RatingBuyLow
12/2/2018CitigroupDowngradeBuy ➝ Neutral$113.00Low
11/26/2018CitigroupDowngradeBuy ➝ Neutral$115.00Low
11/7/2018Societe GeneraleSet TargetHold$106.00High
10/31/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralMedium
10/23/2018Wolfe ResearchInitiated CoverageMarket Perform$119.00Low
10/17/2018Cantor FitzgeraldReiterated RatingBuy$128.00Medium
10/12/2018BarclaysBoost TargetOverweight$112.00 ➝ $120.00Low
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
10/5/2018JPMorgan Chase & Co.Set TargetBuy$123.00Low
10/4/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$107.00 ➝ $130.00High
10/3/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$90.00 ➝ $107.00Medium
10/1/2018SunTrust BanksBoost TargetBuy ➝ Buy$105.00 ➝ $123.00Low
9/27/2018Cantor FitzgeraldSet TargetBuy$110.00Low
9/26/2018JPMorgan Chase & Co.Set TargetNot Rated ➝ Overweight$117.00Low
9/18/2018BarclaysReiterated RatingOverweight$107.00 ➝ $112.00Low
9/17/2018Cantor FitzgeraldSet TargetBuy$110.00Low
9/7/2018BarclaysBoost TargetOverweight ➝ Overweight$98.00 ➝ $107.00Medium
7/31/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$93.00 ➝ $102.00Low
7/31/2018SunTrust BanksReiterated RatingBuy$105.00Low
7/25/2018Bank of AmericaBoost TargetNeutral ➝ Neutral$90.00 ➝ $94.00Medium
7/25/2018Credit Suisse GroupBoost TargetUnderperform ➝ Underperform$84.00 ➝ $86.00High
7/25/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$80.00 ➝ $90.00High
7/25/2018Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$100.00 ➝ $110.00High
7/25/2018Berenberg BankDowngradeBuy ➝ Hold$99.00High
7/25/2018The Goldman Sachs GroupSet TargetNeutral$100.00High
7/24/2018CowenSet TargetBuy$105.00High
7/24/2018Cantor FitzgeraldSet TargetBuy$100.00High
7/19/2018BMO Capital MarketsBoost TargetMarket Perform ➝ $89.43$78.00 ➝ $80.00Medium
7/17/2018Cantor FitzgeraldSet TargetBuy$100.00Low
7/17/2018Bank of AmericaBoost TargetNeutral ➝ Neutral$86.00 ➝ $90.00Low
7/15/2018Jefferies Financial GroupSet TargetBuy$100.00Low
7/13/2018Credit Suisse GroupSet TargetHold$84.00Low
7/9/2018Cantor FitzgeraldSet TargetBuy$100.00Low
6/22/2018DZ BankReiterated RatingBuy ➝ HoldLow
6/21/2018Credit Suisse GroupBoost TargetUnderperform ➝ Underperform$82.00 ➝ $84.00Low
6/11/2018JPMorgan Chase & Co.Set TargetBuy$100.00Low
6/7/2018Cantor FitzgeraldInitiated CoverageOverweight$100.00Low
5/22/2018BarclaysSet TargetBuy$98.00Low
5/15/2018Credit Suisse GroupSet TargetHold$82.00Low
5/10/2018BMO Capital MarketsReiterated RatingHold$78.00Low
4/25/2018BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$79.00 ➝ $78.00Medium
4/24/2018BMO Capital MarketsReiterated RatingHold$79.00Medium
4/22/2018Credit Suisse GroupSet TargetHold$80.00Medium
4/18/2018HC WainwrightReiterated RatingBuyLow
4/13/2018BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$74.00 ➝ $79.00Low
4/13/2018Jefferies Financial GroupSet TargetBuy$90.00Low
4/4/2018BMO Capital MarketsReiterated RatingSell$74.00Medium
3/23/2018Jefferies Financial GroupReiterated RatingBuy$91.00Medium
2/26/2018Jefferies Financial GroupSet TargetBuy$93.00Low
2/26/2018JPMorgan Chase & Co.Set TargetBuy$105.00Medium
2/2/2018Credit Suisse GroupReiterated RatingHold$80.00Low
2/1/2018Bank of AmericaLower TargetNeutral ➝ Neutral$88.00 ➝ $86.00Low
2/1/2018BMO Capital MarketsBoost TargetUnderperform ➝ Underperform$73.00 ➝ $74.00Low
(Data available from 1/31/2018 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 46 positive mentions
  • 7 negative mentions
  • 12 very negative mentions
  • 7 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 76 positive mentions
  • 12 negative mentions
  • 9 very negative mentions
  • 21 very positive mentions
  • 41 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
  • 24 very positive mentions
  • 48 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
  • 30 very positive mentions
  • 87 positive mentions
  • 13 negative mentions
  • 16 very negative mentions
  • 25 very positive mentions
  • 39 positive mentions
  • 12 negative mentions
  • 1 very negative mentions
  • 44 very positive mentions
  • 49 positive mentions
  • 18 negative mentions
  • 9 very negative mentions

Current Sentiment

  • 44 very positive mentions
  • 49 positive mentions
  • 18 negative mentions
  • 9 very negative mentions

Recent Stories by Sentiment

Eli Lilly and logo
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Read More

Today's Range

Now: $340.50
Low: $339.46
High: $347.80

50 Day Range

MA: $361.09
Low: $342.10
High: $374.76

52 Week Range

Now: $340.50
Low: $231.87
High: $384.44


2,580,160 shs

Average Volume

2,542,840 shs

Market Capitalization

$323.54 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?

The following sell-side analysts have issued reports on Eli Lilly and in the last twelve months: Argus, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Daiwa Capital Markets, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and?

19 Wall Street analysts have set twelve-month price targets for Eli Lilly and in the last year. Their average twelve-month price target is $384.11, suggesting a possible upside of 12.8%. Morgan Stanley has the highest price target set, predicting LLY will reach $440.00 in the next twelve months. Daiwa Capital Markets has the lowest price target set, forecasting a price of $286.00 for Eli Lilly and in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and?

Eli Lilly and currently has 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LLY will outperform the market and that investors should add to their positions of Eli Lilly and.
View the latest ratings for LLY.

What other companies compete with Eli Lilly and?

How do I contact Eli Lilly and's investor relations team?

Eli Lilly and's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is [email protected] The official website for Eli Lilly and is www.lilly.com. Learn More about contacing Eli Lilly and investor relations.